Sven Trelle
A5057426061- Meta-analysis and systematic reviews
- Lymphoma Diagnosis and Treatment
- Health Systems, Economic Evaluations, Quality of Life
- Statistical Methods in Clinical Trials
- Osteoarthritis Treatment and Mechanisms
- Erythropoietin and Anemia Treatment
- Ethics in Clinical Research
- Chronic Lymphocytic Leukemia Research
- Eosinophilic Esophagitis
- Lung Cancer Treatments and Mutations
- Venous Thromboembolism Diagnosis and Management
- Inflammatory mediators and NSAID effects
- Viral-associated cancers and disorders
- Musculoskeletal pain and rehabilitation
- Iron Metabolism and Disorders
- Pharmaceutical Practices and Patient Outcomes
- Atrial Fibrillation Management and Outcomes
- Blood transfusion and management
- Clinical practice guidelines implementation
- Kidney Stones and Urolithiasis Treatments
- Medication Adherence and Compliance
- Hip disorders and treatments
- CNS Lymphoma Diagnosis and Treatment
- Cardiac, Anesthesia and Surgical Outcomes
- Orthopaedic implants and arthroplasty
University of Bern
2016-2025
University Hospital of Bern
2009-2023
World Health Organization
2020-2022
Medical Research Council
2020
University of Bristol
2007-2020
Public Health Foundation of India
2020
Indian Council of Medical Research
2020
University of Oxford
2020
Institute of Social and Preventive Medicine
2010-2019
University of Zurich
2019
BackgroundWorld Health Organization expert groups recommended mortality trials of four repurposed antiviral drugs — remdesivir, hydroxychloroquine, lopinavir, and interferon beta-1a in patients hospitalized with coronavirus disease 2019 (Covid-19).MethodsWe randomly assigned inpatients Covid-19 equally between one the trial drug regimens that was locally available open control (up to five options, active local standard care). The intention-to-treat primary analyses examined in-hospital...
rVSV-ZEBOV is a recombinant, replication competent vesicular stomatitis virus-based candidate vaccine expressing surface glycoprotein of Zaire Ebolavirus. We tested the effect in preventing Ebola virus disease contacts and recently confirmed cases Guinea, west Africa.
<h3>Context</h3>The efficacy and safety of drug-eluting stents compared with bare-metal remains controversial in patients ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI).<h3>Objective</h3>To compare eluting biolimus from a biodegradable polymer PCI.<h3>Design, Setting, Patients</h3>A prospective, randomized, single-blinded, controlled trial 1161 presenting STEMI at 11 sites Europe Israel between September 19, 2009, January 25,...
Abstract Objective To examine the effect of optimising drug treatment on related hospital admissions in older adults with multimorbidity and polypharmacy admitted to hospital. Design Cluster randomised controlled trial. Setting 110 clusters inpatient wards within university based hospitals four European countries (Switzerland, Netherlands, Belgium, Republic Ireland) defined by attending doctors. Participants 2008 (≥70 years) (≥3 chronic conditions) (≥5 drugs used long term). Intervention...
The effect of early as compared with later initiation direct oral anticoagulants (DOACs) in persons atrial fibrillation who have had an acute ischemic stroke is unclear.We performed investigator-initiated, open-label trial at 103 sites 15 countries. Participants were randomly assigned a 1:1 ratio to anticoagulation (within 48 hours after minor or moderate on day 6 7 major stroke) (day 3 4 stroke, 12, 13, 14 stroke). Assessors unaware the trial-group assignments. primary outcome was composite...
Nephrolithiasis is one of the most common conditions affecting kidney and characterized by a high risk recurrence. Thiazide diuretic agents are widely used for prevention recurrence stones, but data regarding efficacy such as compared with placebo limited. Furthermore, dose–response also
To determine the efficacy and safety of a newly developed concomitant administration fludarabine alemtuzumab (FluCam) in patients with relapsed or refractory B-cell chronic lymphocytic leukemia (B-CLL).A total 36 were treated this phase II study (median age, 61.47 years; mean number prior chemotherapies, 2.6; Binet stage C, n = 28). After an initial dose escalation over 3 days, 30 mg mg/m2 administered on consecutive days. Treatment was repeated after 28 days for up to six cycles. Restaging...